Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 119.29B, Vertex Pharmaceuticals(VRTX) trades at $469.90. The stock has a price-to-earnings ratio of 33.12.
As of 2026-02-02, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $468.23 and $475.56. The current price stands at $469.90, placing the stock +0.4% above today's low and -1.2% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.03M, compared to an average daily volume of 1.61M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
If you are wondering whether Vertex Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock last closed at US$469...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $564.00. Claim 50% Off TipRanks Premi...
A prominent investment fund has fully exited Vertex Pharmaceuticals (VRTX) after the company said it does not see a path to a broad neuropathic chronic pain lab...
Analyst ratings
72%
of 36 ratingsMore VRTX News
The biotech could be on the verge of expanding its lineup and entering a new era of growth. Despite a few setbacks, Vertex Pharmaceuticals (VRTX +0.86%) perfor...
In recent weeks, Vertex Pharmaceuticals has attracted a series of analyst upgrades and favorable research reports highlighting the strength of its cystic fibros...
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $535 and keeps a Buy rating on the shares. The U.S. Pharmaceuticals and Biotech...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.